Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Zhuang, Peng Yuan ^a   Wang, Jian Dong ^a   Tang, Zhao Hui ^a   Zhou, Xue Ping ^a   Quan, Zhi Wei ^a   Liu, Ying Bin ^a   Shen, Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

gp130; IL 6; Peritumoral endothelial cell; SIL 6R; Tumor endothelial cell

Indexed keywords

CD68 ANTIGEN; GLYCOPROTEIN GP 130; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; IL6 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL HYPOXIA; CELL PROLIFERATION; CELL SPECIFICITY; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PERITUMORAL ENDOTHELIAL CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; TUMORAL ENDOTHELIAL CELL; UPREGULATION; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINE RECEPTOR GP130; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; LIVER NEOPLASMS; MICE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT;

EID: 84945928726     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1763-2     Document Type: Article

References (36)

1. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007;38:258-68.
2. Wang WQ, Liu L, Sun HC, Fu YL, Xu HX, Chai ZT, et al. Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. J Hematol Oncol. 2012;5:69.
3. Yu D, Zhuang L, Sun X, Chen J, Yao Y, Meng K, et al. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. BMC Cancer. 2007;7:122.
4. Yu GR, Kim SH, Park SH, Cui XD, Xu DY, Yu HC, et al. Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp Mol Med. 2007;39:641-52.
5. Zhuang PY, Shen J, Zhu XD, Lu L, Wang L, Tang ZY, et al. Prognostic roles of cross-talk between peritumoral hepatocytes and stromal cells in hepatocellular carcinoma involving peritumoral VEGF-C, VEGFR-1 and VEGFR-3. PLoS One. 2013;8:e64598.
6. Jia JB, Zhuang PY, Sun HC, Zhang JB, Zhang W, Zhu XD, et al. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol. 2009;135:847-54.
7. Xu HX, Zhu XD, Zhuang PY, Zhang JB, Zhang W, Kong LQ, et al. Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer. 2010;128:1559-69.
8. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99-111.
9. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707-16.
10. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med. 2003;9:713-25.
11. Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP, et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 2006;66:3360-4.
12. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004;64:8249-55.
13. Grover AC, Tangrea MA, Woodson KG, Wallis BS, Hanson JC, Chuaqui RF, et al. Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J Transl Med. 2006;4:13.
14. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197-202.
15. Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res. 2009;15:4838-46.
16. Tang S, Yuan Y, He Y, Pan D, Zhang Y, Liu Y, et al. Genetic polymorphism of interleukin-6 influences susceptibility to HBV-related hepatocellular carcinoma in a male Chinese Han population. Hum Immunol. 2014;75:297-301.
17. Hoshida Y, Sangiovanni A, et al. Gene expression signature predicts outcome of liver cirrhosis. Hepatology. 2009;50:312A.
18. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995-2004.
19. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46:1223-31.
20. Jee SH, Chu CY, Chiu HC, Huang YL, Tsai WL, Liao YH, et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol. 2004;123:1169-75.
21. Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res. 2005;25:241-53.
22. Knupfer H, Preiss R. sIL-6R: more than an agonist? Immunol Cell Biol. 2008;86:87-91.
23. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology. 2000;32:43-8.
24. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458-65.
25. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416-23.
26. Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol. 1994;24:1945-8.
27. Briso EM, Dienz O, Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol. 2008;180:7102-6.
28. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, et al. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg. 2003;7:587-94.
29. Wada H, Nagano H, Yamamoto H, Arai I, Ota H, Nakamura M, et al. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep. 2007;18:801-9.
30. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437-48.
31. Zhuang PY, Zhang JB, Zhang W, Zhu XD, Liang Y, Xu HX, et al. Long-term interferon-alpha treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:1891-900.
32. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood. 2007;110:1748-55.
33. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10:6.
34. Fuertes M, Gerez J, Haedo M, Giacomini D, Paez-Pereda M, Labeur M, et al. Cytokines and genes in pituitary tumorigenesis: RSUME role in cell biology. Front Horm Res. 2010;38:1-6.
35. Aird WC. Mechanisms of endothelial cell heterogeneity in health and disease. Circ Res. 2006;98:159-62.
36. Xiong YQ, Sun HC, Zhu XD, Zhang W, Zhuang PY, Zhang JB, et al. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression. J Cancer Res Clin Oncol. 2011;137:505-12.